41.7% of patients showed a Partial Response to the combination therapy of eftilagimod alpha and avelumab (previously 33%)Encouraging early anti-tumour […]
NEW YORK, Sept. 17, 2020 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQ: CKPT), a clinical-stage immunotherapy […]